Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho-related GTP-binding protein RhoV (RHOV) is an atypical member of the Rho family of small GTPases, sharing features with Rac and Cdc42 subfamilies. Distinct from classic Rho proteins, RhoV contains unique N- and C-terminal extensions and is post-translationally modified by palmitoylation but not prenylation. It regulates the dynamics of the actin cytoskeleton, particularly through participation in signal transduction pathways including the c-Jun N-terminal kinase (JNK) pathway. RhoV alters cell shape and cell adhesion, contributing to processes such as epithelial morphogenesis and heart development, but the detailed molecular mechanisms are still under investigation. No direct small molecule inhibitors or drugs targeting RhoV are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho-related GTP-binding protein RhoV (RHOV).